» Articles » PMID: 7661940

A Syndrome of Lymphoblastic Lymphoma, Eosinophilia, and Myeloid Hyperplasia/malignancy Associated with T(8;13)(p11;q11): Description of a Distinctive Clinicopathologic Entity

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1995 Apr 1
PMID 7661940
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

We report two patients with a distinctive biphenotypic hematologic disorder characterized by lymphoblastic lymphoma (LBL), eosinophilia, and myeloid malignancy and/or hyperplasia associated with a t(8;13)(p11;q11) chromosomal translocation in both bone marrow and lymph node specimens. Both patients presented with lymphadenopathy pathologically classified as LBL with a T-cell immunophenotype, myeloid hyperplasia of the bone marrow, and peripheral blood eosinophilia. The first patient achieved clinical complete remission after receiving several regimens of chemotherapy and remains disease-free 16 months after undergoing allogeneic bone marrow transplantation. The second patient developed progressive lymphadenopathy despite several courses of chemotherapy directed against non-Hodgkin's lymphoma. Eight months after his initial presentation, he developed acute myelogenous leukemia that was refractory to therapy. Comparison of these patients with four similar cases recently reported in the literature suggests that this constellation of findings constitutes a distinctive clinicopathologic syndrome. Molecular analysis of the t(8;13) translocation breakpoint may identify genes located in this region and provide insight into the pathogenesis of this interesting biphenotypic hematologic malignancy.

Citing Articles

Myeloid and lymphoid neoplasm with novel complex translocation: unusual case report with T-lymphoblastic lymphoma, myeloid hyperplasia, eosinophilia, basophilia, and t(1;8;10)( (p31;q24;q11.2).

Aljabry M J Hematop. 2024; 16(1):27-31.

PMID: 38175368 DOI: 10.1007/s12308-022-00528-1.


Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.

Sircar A, Singh S, Xu-Monette Z, Coyle K, Hilton L, Chavdoula E Leukemia. 2023; 37(10):2094-2106.

PMID: 37598282 PMC: 10539170. DOI: 10.1038/s41375-023-02006-8.


Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT.

Hernandez-Boluda J, Pereira A, Zinger N, Gras L, Martino R, Nikolousis E Bone Marrow Transplant. 2022; 57(3):416-422.

PMID: 35066569 DOI: 10.1038/s41409-021-01553-x.


Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment.

Cowell J, Hu T Cancer Drug Resist. 2021; 4:607-619.

PMID: 34734169 PMC: 8562765. DOI: 10.20517/cdr.2021.30.


Identification of autofluorescent cells in human angioimmunoblastic T-cell lymphoma.

Buchwalow I, Atiakshin D, Samoilova V, Boecker W, Tiemann M Histochem Cell Biol. 2017; 149(2):169-177.

PMID: 29197996 DOI: 10.1007/s00418-017-1624-y.